| Theme | Clinical research in the field of CKD-MBD | |
|---|---|---|
| Title | Role of vitamin K in patients with CKD-MBD | |
| Publish Date | 2014/10 | |
| Author | Ayumu Nakashima | Department of Regeneration and Medicine, Hiroshima University Hospital |
| Author | Takao Masaki | Department of Nephrology, Hiroshima University Hospital |
| [ Summary ] | Vitamin K is an essential cofactor for site-specific carboxylation of osteocalcin. It also promotes bone formation. In addition, vitamin K2 therapy can prevent the occurrence of new fractures in osteoporosis patients. On the other hand, vitamin K is an essential cofactor for site-specific carboxylation of matrix Gla protein, which prevent vascular calcification. Chronic kidney diseasemineral and bone disorder : CKD-MBD is a concept which has been proposed not only in terms of abnormal bone metabolism but also in relation to systemic disease, including vascular calcification associated with CKD. Because of these conclusions, vitamin K has become a candidate for an interesting therapeutic medication for CKD-MBD patients. | |